FIRALIS
BRIDGING SCIENCE TO CLINICS

Innovation & Biomarkers

Accelerate your Oncology Research with the unique solutions for genomics biomarker investigation of FIRALIS

FIRALIS provides exclusively in Europe the largest multiplex measurement of gene expression of more than 2'560 oncogenes in solid fresh or FFPE biopsy samples, even for very degraded and long-stored materials.

This innovative service for oncogenes mRNA measurement is performed with unmet inter-run reproducibility* by Oncology Biomarker® Panel HTG EdgeSeq. The instrument is based on a unique principle of extraction-free chemistry, which avoids all biases associated with classical steps such as RNA extraction, cDNA synthesis and ligations performed during traditional qPCR protocols.

The best cost-effective instrument for RNAs measurement coupled to Next Generation Sequencing Illumina NextSeq 500

An ultra-minimal sample input to get thousands of comprehensive data

Key advantages of the HTG oncogene panel:

- Extraction-free chemistry
- Very high reproducibility (*R^2> 0.97)
- High sensitivity of the next generation sequencing

HTG Minimal sample input needed:

- 0,8 to 10mm^2 on 5µm-thicked FFPE slides or fresh tissues
- 32µL of whole blood in PAXgene tubes
- 1,5 to 10 ng purified RNA



The ultimate onco-RNAs measurement screening up to 2560 mRNAs for only EUR 370 per sample

Extended FIRALIS GCLP compliant Services based on NGS Illumina NextSeq 500 enable also to accelerate your oncology research by focusing on 3 cutting-edge panels such as:

- ✓ Cancer Panel TruSeq Amplicon
  High sensitive mutation detection within important cancer-related genes (48 targeted genes)
  FIRALIS recommends this method to explore key cell-pathways according to a specific tumor-kind.

- ✓ Cancer Whole-Exome Sequencing
  Focus only coding regions to assess tumor progression among sample collection fresh, frozen or FFPE.

  FIRALIS recommends this method of choice for many tumor-normal tissue comparisons.
- ✓ RNA Seq / whole transcriptome analysis
  Comprehensive overview of transcriptome for identification of somatic variants associated with tumor genesis and progression.
  FIRALIS recommends this high sensitive method of detection regarding your projects targeting whole transcriptomes (mRNA, miRNA, lncRNA) and potential occurring mutations.

FIRALIS Biomarkers Services provide you tailored solutions for your personal projects with high accurate measurements of several RNA-kinds and a targeted sequencing, employing cutting-edge technological platforms and a high-experienced PhD-level team with dedicated project managers.

Contact us at sales@firalis.com to get further details about **FIRALIS Biomarker Services** and our capabilities to successfully level up your personal projects.